Phathom Pharmaceuticals Showcases Innovative VOQUEZNA at ACG Meeting
Highlighting VOQUEZNA at ACG 2025 Annual Scientific Meeting
FLORHAM PARK, N.J. — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a dedicated biopharmaceutical company, is actively engaging in the American College of Gastroenterology’s (ACG) Annual Scientific Meeting, highlighting its commitment to innovative treatments for gastrointestinal (GI) diseases. This year’s event will take place in Phoenix, providing a platform for Phathom to interact with the medical community as they unveil the benefits of VOQUEZNA (vonoprazan).
Engagements at the Event
Phathom will demonstrate its expanding leadership in GI through various presentations aimed at medical professionals. Notably, the company will host a product theater to discuss VOQUEZNA (vonoprazan) tablets, which have been approved for treating Gastroesophageal Reflux Disease (GERD). CEO Steve Basta expressed enthusiasm about this opportunity: “We’re eager to connect with the GI community at ACG, sharing insights and reinforcing our commitment to enhancing outcomes for patients affected by GI disorders.”
Event Schedule and Presentations
The schedule for Phathom’s activities at the ACG meeting is as follows:
- Exhibit Booth: Attendees can visit Phathom’s Medical Affairs and Commercial teams at Booth #214 from October 26 to 29.
- Monday Presentation: On October 27, from 3:45 pm to 4:30 pm MST, join the product theater titled "Expert Insights on GERD Therapy: A Case-Based Approach with a First-in-Class Acid Suppressant," led by Dr. John Erik Pandolfino, a renowned expert in gastroenterology.
Phathom is also proud to support an independent medical education program focused on GERD management, which takes place on October 25, emphasizing the importance of informed treatment decisions.
Understanding VOQUEZNA
VOQUEZNA (vonoprazan) is a potassium-competitive acid blocker (PCAB) designed to address GI issues. It has been beneficial for adults in several ways:
- Healing all grades of Erosive Esophagitis and relieving heartburn associated with Erosive GERD.
- Maintaining healing of Erosive GERD and managing heartburn symptoms.
- Offering relief for heartburn linked to Non-Erosive GERD.
Considering the impact VOQUEZNA has on patient quality of life, ongoing studies and presentations like those at the ACG are vital for reinforcing the knowledge surrounding its application.
Safety and Efficacy Information
As with any medical treatment, VOQUEZNA comes with essential safety information. Awareness around potential contraindications, especially for those with known hypersensitivity to its components, is crucial. Moreover, any symptomatic responses to therapy should be monitored as they do not rule out other serious conditions.
Patients using VOQUEZNA should remain vigilant for signs of acute tubulointerstitial nephritis, which has been associated with this treatment. Additionally, it’s important to understand the risks linked to long-term use, including the potential for osteoporosis-related fractures and other adverse reactions.
Regular monitoring and communication with healthcare providers can significantly enhance the treatment experience, ensuring safety and efficacy are prioritized.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a frontrunner in the biopharmaceutical industry, dedicated to pioneering therapeutic solutions for gastrointestinal diseases. With exclusive rights to market vonoprazan in the U.S., Europe, and Canada, Phathom showcases its innovative approach through products like VOQUEZNA® and its associated treatment packs for H. pylori infection.
For insight on the latest developments and information about their offerings, visit Phathom’s website.
Frequently Asked Questions
What is VOQUEZNA?
VOQUEZNA (vonoprazan) is a potassium-competitive acid blocker used to treat GERD and related conditions.
When will Phathom be at the ACG meeting?
Phathom will participate in the ACG meeting from October 26 to 29.
What kind of presentations will Phathom provide at ACG?
Phathom will showcase a product theater and host discussions around VOQUEZNA, including insights from leading experts.
How does VOQUEZNA work?
VOQUEZNA functions by blocking acid secretion in the stomach, providing relief from GERD symptoms.
Who should use VOQUEZNA?
VOQUEZNA is intended for adults with Erosive GERD or Non-Erosive GERD. Patients should consult their doctors to ensure it's suitable for their condition.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.